Foghorn Therapeutics Files 8-K, Announces AACR Preclinical Data (Apr 2026)

What Happened

• Foghorn Therapeutics Inc. filed a Current Report on Form 8-K on April 21, 2026 (Items 7.01 and 8.01) and furnished an investor presentation dated April 2026.
• The company issued a press release (attached as Exhibit 99.2) announcing preclinical data presented in multiple posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, including data on SMARCA2-selective inhibitor FHD-909 and selective degraders targeting CBP, EP300 and ARID1B.

Key Details

• Filing date: April 21, 2026 (Form 8-K reporting Items 7.01 and 8.01).
• Investor presentation: Exhibit 99.1, dated April 2026.
• Programs highlighted: FHD-909 (SMARCA2 selective inhibitor) and degrader programs for CBP, EP300 and ARID1B.
• The 8-K includes the company’s standard forward-looking statements and directs readers to risk factors in its 2025 Form 10-K.

Why It Matters

• The announcement provides investors with new preclinical data from AACR that updates progress across Foghorn’s oncology pipeline—useful for assessing program advancement and R&D focus.
• These are preclinical results only; the filing does not report clinical trial outcomes, financial results, or new regulatory filings. Forward-looking statements and referenced 10-K risk factors underscore that future clinical or commercial success is uncertain.